Sidoti & Co. Downgrades Surmodics to Neutral, Announces $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Sidoti & Co. has downgraded Surmodics (NASDAQ:SRDX) from Buy to Neutral and set a price target of $43.
May 29, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sidoti & Co. has downgraded Surmodics from Buy to Neutral and set a price target of $43. This downgrade may lead to a short-term negative impact on the stock price as investor sentiment adjusts.
The downgrade from Buy to Neutral by a reputable analyst firm like Sidoti & Co. typically signals a less optimistic outlook on the stock, which can lead to a decrease in investor confidence and a potential short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100